Rx RadioRx Radio
HomePodcastResourcesDataShopNewsBusinessTechnologyClinical PracticeCommunity Pharmacy
HomePodcastResourcesDataShopArticlesCategoriesSearchAbout

Categories

NewsBusinessTechnologyClinical PracticeCommunity PharmacyDrug Pricing and AccessEducationEducation and TrainingGlobal HealthLaw and ComplianceLeadership and DevelopmentManaged CareOTC ProductsPatient Care & CounselingPharmacy TechnologyPublic HealthResearch and Development
Rx RadioRx Radio

Leading the conversation in pharmacy.

Navigation

  • Home
  • Podcast
  • Resources
  • Data
  • Shop
  • Articles
  • Categories
  • Search

Categories

  • News
  • Business
  • Technology
  • Clinical Practice
  • Community Pharmacy
  • Drug Pricing and Access
  • Education

Company

  • About
  • Privacy Policy
  • Terms of Service

Follow Us

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • TikTok
  • Threads

© 2026 Rx Radio. All rights reserved.

PrivacyTerms

Leif Hanson

Articles by Leif Hanson

Lyra Therapeutics Suspends Development of LYR-210 for Chronic Rhinosinusitis Despite Positive Trial Results
News

Lyra Therapeutics Suspends Development of LYR-210 for Chronic Rhinosinusitis Despite Positive Trial Results

Lyra Therapeutics halts development of LYR-210 for chronic rhinosinusitis despite positive Phase 3 results, cutting workforce and exploring strategic alternatives.

Jan 14, 2026
Transforming STI Care: The Impact of FDA-Approved At-Home Testing
Patient Care & Counseling

Transforming STI Care: The Impact of FDA-Approved At-Home Testing

The FDA has authorized Visby Medical's at-home test for chlamydia, gonorrhea, and trichomoniasis, marking a major advancement in sexual health testing accessibility.

Jan 19, 2026
Roche's CT-388 Achieves 22.5% Weight Loss in Phase 2 Trial
News

Roche's CT-388 Achieves 22.5% Weight Loss in Phase 2 Trial

Roche's investigational obesity drug CT-388 demonstrated 22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 trial, advancing to Phase 3 studies.

Feb 2, 2026
FDA Removes REMS Program for Clozapine Despite Neutropenia Risk
News

FDA Removes REMS Program for Clozapine Despite Neutropenia Risk

FDA eliminates mandatory safety program for clozapine, citing access concerns while acknowledging ongoing neutropenia risk for patients.

Jun 13, 2025
FDA Launches PreCheck Pilot Program, Aimed at Strengthening U.S. Drug Manufacturing
News

FDA Launches PreCheck Pilot Program, Aimed at Strengthening U.S. Drug Manufacturing

FDA's new PreCheck pilot program aims to boost domestic drug manufacturing through streamlined regulatory pathways and early facility engagement.

Feb 2, 2026